| 5-R01-EB032726-03 |
Engineered BacNav and BacCav for Improved Excitability and Contraction |
Nenad Bursac |
Duke University |
| 5-R21-EB033841-02 |
Engineering and Testing of Biomimetic Stimulators for Therapeutic Applications |
Michael Kuhns |
University of Arizona |
| 5-R01-EB035016-02 |
Engineering human-derived programmable RNA effectors to retune gene expression |
Bryan Dickinson |
University of Chicago |
| 1-R01-EB036003-01 |
Engineering therapeutic cellular functions using robust and highly programmable extrachromosomal genetic technologies |
Isaac Hilton |
Rice University |
| 5-R01-EB033389-02 |
Homogenized, engineered extracellular vesicles for intracranial targeting |
Randy Carney |
University of California at Davis |
| 1-R21-EB033963-01A1 |
Mitigating the Immunogenicity of Engineered Aav Gene Delivery Vectors by Biomaterial-Driven Immunosuppression |
Shaoyi Jiang |
Cornell University |
| 5-R01-EB031904-04 |
Multiplexed and Logical Control of the Mammalian Transcriptome Using Cas13 |
Wilson Wong |
Boston University (Charles River Campus) |
| 1-R21-EB034346-01A1 |
Next generation of delivery platform for Prime editors based on an RNA vector for Sickle cell disease: the “all-in-one” vector |
Patricia Devaux |
Mayo Clinic Rochester |
| 5-R01-EB033676-03 |
Next generation transposon vectors for genome engineering |
Matthew Wilson |
Vanderbilt University Medical Center |
| 5-R21-EB032609-02 |
Novel optogenetic tool for noninvasive neuronal inhibition |
Mark Gomelsky |
University of Wyoming |
